Literature DB >> 21709826

Preeclampsia and the Anti-Angiogenic State.

Isha Agarwal1, S Ananth Karumanchi.   

Abstract

Preeclampsia is a major cause of maternal and fetal morbidity and mortality worldwide, however, its etiology remains unclear. Abnormal placental angiogenesis during pregnancy resulting from high levels of anti-angiogenic factors, soluble Flt1 (sFlt1) and soluble endoglin (sEng), has been implicated in preeclampsia pathogenesis. Accumulating evidence also points to a role for these anti-angiogenic proteins as serum biomarkers for the clinical diagnosis and prediction of preeclampsia. Uncovering the mechanisms of altered angiogenic factors in preeclampsia may also provide insights into novel preventive and therapeutic options.

Entities:  

Year:  2011        PMID: 21709826      PMCID: PMC3087187          DOI: 10.1016/j.preghy.2010.10.007

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  56 in total

Review 1.  Strategies to prevent and treat preeclampsia: evidence from randomized controlled trials.

Authors:  José Villar; Edgardo Abalos; Juan M Nardin; Mario Merialdi; Guillermo Carroli
Journal:  Semin Nephrol       Date:  2004-11       Impact factor: 5.299

Review 2.  Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights.

Authors:  Yuval Bdolah; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  Semin Nephrol       Date:  2004-11       Impact factor: 5.299

3.  VEGF mRNA is unaltered in decidual and placental tissues in preeclampsia at delivery.

Authors:  T Ranheim; A C Staff; T Henriksen
Journal:  Acta Obstet Gynecol Scand       Date:  2001-02       Impact factor: 3.636

Review 4.  Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.

Authors:  M Shibuya
Journal:  Cell Struct Funct       Date:  2001-02       Impact factor: 2.212

5.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Samuel S Edwin; Ricardo Gomez; Lami Yeo; Agustin Conde-Agudelo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

6.  Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia.

Authors:  Valeria C Sandrim; Ana C T Palei; Ingrid F Metzger; Valeria A Gomes; Ricardo C Cavalli; Jose E Tanus-Santos
Journal:  Hypertension       Date:  2008-06-23       Impact factor: 10.190

7.  Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.

Authors:  Zhihe Li; Ying Zhang; Jing Ying Ma; Ann M Kapoun; Qiming Shao; Irene Kerr; Andrew Lam; Gilbert O'Young; Frederick Sannajust; Peter Stathis; George Schreiner; S Ananth Karumanchi; Andrew A Protter; N Stephen Pollitt
Journal:  Hypertension       Date:  2007-08-27       Impact factor: 10.190

8.  Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences.

Authors:  Vassilis Tsatsaris; Frederic Goffin; Carine Munaut; Jean-François Brichant; Marie-Rose Pignon; Agnes Noel; Jean-Pierre Schaaps; Dominique Cabrol; Francis Frankenne; Jean-Michel Foidart
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

9.  A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia.

Authors:  Christie P Thomas; Janet I Andrews; Nandita S Raikwar; Elizabeth A Kelley; Florian Herse; Ralf Dechend; Thaddeus G Golos; Kang Z Liu
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

Review 10.  Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Authors:  T Kamba; D M McDonald
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

View more
  21 in total

1.  Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia.

Authors:  Nandor Gabor Than; Roberto Romero; Adi Laurentiu Tarca; Katalin Adrienna Kekesi; Yi Xu; Zhonghui Xu; Kata Juhasz; Gaurav Bhatti; Ron Joshua Leavitt; Zsolt Gelencser; Janos Palhalmi; Tzu Hung Chung; Balazs Andras Gyorffy; Laszlo Orosz; Amanda Demeter; Anett Szecsi; Eva Hunyadi-Gulyas; Zsuzsanna Darula; Attila Simor; Katalin Eder; Szilvia Szabo; Vanessa Topping; Haidy El-Azzamy; Christopher LaJeunesse; Andrea Balogh; Gabor Szalai; Susan Land; Olga Torok; Zhong Dong; Ilona Kovalszky; Andras Falus; Hamutal Meiri; Sorin Draghici; Sonia S Hassan; Tinnakorn Chaiworapongsa; Manuel Krispin; Martin Knöfler; Offer Erez; Graham J Burton; Chong Jai Kim; Gabor Juhasz; Zoltan Papp
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

Review 2.  Vascular Dysfunction in Mother and Offspring During Preeclampsia: Contributions from Latin-American Countries.

Authors:  Fernanda Regina Giachini; Carlos Galaviz-Hernandez; Alicia E Damiano; Marta Viana; Angela Cadavid; Patricia Asturizaga; Enrique Teran; Sonia Clapes; Martin Alcala; Julio Bueno; María Calderón-Domínguez; María P Ramos; Victor Vitorino Lima; Martha Sosa-Macias; Nora Martinez; James M Roberts; Carlos Escudero
Journal:  Curr Hypertens Rep       Date:  2017-10-06       Impact factor: 5.369

3.  Concentrations of endothelial nitric oxide synthase, angiotensin-converting enzyme, vascular endothelial growth factor and placental growth factor in maternal blood and maternal metabolic status in pregnancy complicated by hypertensive disorders.

Authors:  A Zawiejska; E Wender-Ozegowska; R Iciek; J Brazert
Journal:  J Hum Hypertens       Date:  2014-09-04       Impact factor: 3.012

4.  Protective Low-Frequency Variants for Preeclampsia in the Fms Related Tyrosine Kinase 1 Gene in the Finnish Population.

Authors:  A Inkeri Lokki; Emma Daly; Michael Triebwasser; Mitja I Kurki; Elisha D O Roberson; Paavo Häppölä; Kirsi Auro; Markus Perola; Seppo Heinonen; Eero Kajantie; Juha Kere; Katja Kivinen; Anneli Pouta; Jane E Salmon; Seppo Meri; Mark Daly; John P Atkinson; Hannele Laivuori
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

5.  Epigenetics and microRNAs in preeclampsia.

Authors:  Mahua Choudhury; Jacob E Friedman
Journal:  Clin Exp Hypertens       Date:  2012-04-02       Impact factor: 1.749

6.  Timing of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat.

Authors:  Christopher T Banek; Ashley J Bauer; Anne Gingery; Jeffrey S Gilbert
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-07-25       Impact factor: 3.619

Review 7.  Angiogenic factors in diagnosis, management, and research in preeclampsia.

Authors:  Sarosh Rana; S Ananth Karumanchi; Marshall D Lindheimer
Journal:  Hypertension       Date:  2013-10-28       Impact factor: 10.190

8.  An exploratory study of white blood cell proportions across preeclamptic and normotensive pregnancy by self-identified race in individuals with overweight or obesity.

Authors:  Mitali Ray; Lacey W Heinsberg; Yvette P Conley; James M Roberts; Arun Jeyabalan; Carl A Hubel; Daniel E Weeks; Mandy J Schmella
Journal:  Hypertens Pregnancy       Date:  2021-10-26       Impact factor: 2.108

Review 9.  A comprehensive review of hypertension in pregnancy.

Authors:  Reem Mustafa; Sana Ahmed; Anu Gupta; Rocco C Venuto
Journal:  J Pregnancy       Date:  2012-05-23

Review 10.  Biomarkers for the management of pre-eclampsia in pregnant women.

Authors:  Lakshmi Tanuja Petla; Rosy Chikkala; K S Ratnakar; Vijayalakshmi Kodati; V Sritharan
Journal:  Indian J Med Res       Date:  2013       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.